Pre-existing hypertension is associated with poor progression-free survival in newly diagnosed multiple myeloma patients

被引:0
|
作者
Zhang, Xiaomin [1 ]
Yang, Jieli [1 ]
Chen, Sai [1 ]
Liu, Chang [1 ]
Wang, Zhenhua [1 ]
Ren, Hefei [1 ]
Zhou, Lin [1 ]
机构
[1] Naval Med Univ, Shanghai Changzheng Hosp, Dept Lab Med, 415 Fengyang Rd, Shanghai 200003, Peoples R China
基金
芬兰科学院; 中国国家自然科学基金;
关键词
Hypertension; Multiple myeloma; Progression-free survival; Risk stratification; BLOOD-PRESSURE; PARATHYROID-HORMONE; CANCER; RISK; CELLS; INTERLEUKIN-6; INFLAMMATION; MEDICATIONS; CALCIUM;
D O I
10.1007/s11239-022-02653-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Approximately 31% of patients diagnosed with multiple myeloma (MM) have pre-existing hypertension, but its effects on patient survival have not been investigated. We collected data from 228 newly diagnosed patients with MM and found that 71 (31.1%) had pre-existing hypertension. The impact of pre-existing hypertension on MM patients was determined by evaluating progression-free survival (PFS). Kaplan-Meier analyses revealed a significantly lower PFS in the pre-existing hypertension group than their non-hypertensive counterparts (median 22.6 vs 34.8 months, respectively). The multivariable Cox proportional hazards model showed that pre-existing hypertension was an independent risk factor for PFS reduction in MM patients. Moreover, the risk of disease progression in MM patients with pre-existing hypertension was higher than in non-hypertension comparator patients (hazard ratio 1.735, 95% confidence interval 1.261-2.387). In MM patients with pre-existing hypertension, Kaplan-Meier analyses found that those with a higher risk of hypertension had a significantly shorter PFS than those with lower risk (median 19.3 vs 25.4 months, respectively). However, multivariate Cox regression analysis showed that the risk stratification of hypertension was not an independent risk factor for poor PFS in MM patients with pre-existing hypertension. Our study demonstrates that pre-existing hypertension was significantly associated with a lower PFS in newly diagnosed MM patients.
引用
收藏
页码:542 / 549
页数:8
相关论文
共 50 条
  • [21] Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma: TAURUS Chart Review Study
    Gordan, Lucio Navarro
    Tan, Carlyn Rose
    Vescio, Robert
    Ye, Jing Christine
    Schinke, Carolina
    Medhekar, Rohan
    Fu, Alex Z.
    Lafeuille, Marie-Helene
    Thompso-Leduc, Philippe
    Khare, Vipin
    Reitan, John
    Milkovich, Gary
    Kaila, Shuchita
    Davies, Faith
    Usmani, Saad Z.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (01) : 55 - 63
  • [22] Construction and validation of an 18F-FDG-PET/CT-based prognostic model to predict progression-free survival in newly diagnosed multiple myeloma patients
    Dong, Xiaoqing
    Wang, Ruoyi
    Ying, Xiuhua
    Xu, Jiaxuan
    Yan, Jie
    Xu, Peipei
    Peng, Yue
    Chen, Bing
    HEMATOLOGY, 2024, 29 (01)
  • [23] Progression-Free Survival of Daratumumab vs Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Newly Diagnosed Multiple Myeloma Patients: TAURUS Chart Review Study
    Gordan, Lucio
    Tan, Carlyn Rose
    Vescio, Robert
    Ye, Jing Christine
    Schinke, Carolina
    Medhekar, Rohan
    Fu, Alex Z.
    Lafeuille, Marie-Helene
    Thompson-Leduc, Philippe
    Khare, Vipin
    Reitan, John
    Milkovich, Gary
    Kaila, Shuchita
    Davies, Faith
    Usmani, Saad Z.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S502 - S502
  • [24] Body Mass Index and Overall Survival of Patients with Newly Diagnosed Multiple Myeloma
    Wang, Bei
    Derman, Benjamin A.
    Langerman, Spencer S.
    Johnson, Julie
    Zhang, Wei
    Jakubowiak, Andrzej
    Chiu, Brian C-H
    CANCERS, 2022, 14 (21)
  • [25] Levels of uninvolved immunoglobulins predict clinical status and progression-free survival for multiple myeloma patients
    Harutyunyan, Nika M.
    Vardanyan, Suzie
    Ghermezi, Michael
    Gottlieb, Jillian
    Berenson, Ariana
    Andreu-Vieyra, Claudia
    Berenson, James R.
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 174 (01) : 81 - 87
  • [26] Extreme body mass index and survival in newly diagnosed multiple myeloma patients
    Shah, Urvi A. A.
    Whiting, Karissa
    Devlin, Sean
    Ershler, Rachel
    Kanapuru, Bindu
    Lee, David J. J.
    Tahri, Sabrin
    Gwise, Thomas
    Rustad, Even H. H.
    Mailankody, Sham
    Lesokhin, Alexander M. M.
    Kazandjian, Dickran
    Maura, Francesco
    Auclair, Daniel
    Birmann, Brenda M. M.
    Usmani, Saad Z. Z.
    Gormley, Nicole
    Marinac, Catherine R. R.
    Landgren, Ola
    BLOOD CANCER JOURNAL, 2023, 13 (01)
  • [27] Establishment of a prediction model for disease progression within one year in newly diagnosed multiple myeloma patients
    Wei, Huahua
    Sun, Zhihuang
    Ye, Xiaoying
    Yu, Jieni
    Ye, Yinhai
    Wang, Zifeng
    HEMATOLOGY, 2022, 27 (01) : 575 - 582
  • [28] XRCC1-mediated DNA repair is associated with progression-free survival of multiple myeloma patients after autologous stem cell transplant
    Persaud, Avinash K.
    Li, Junan
    Johnson, Jasmine A.
    Seligson, Nathan
    Sborov, Douglas W.
    Duah, Ernest
    Cho, Yu Kyoung
    Wang, Danxin
    Phelps, Mitch A.
    Hofmeister, Craig C.
    Poi, Ming J.
    MOLECULAR CARCINOGENESIS, 2019, 58 (12) : 2327 - 2339
  • [29] Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma
    Ludwig, Heinz
    Adam, Zdenek
    Tothova, Elena
    Hajek, Roman
    Labar, Boris
    Egyed, Miklos
    Spicka, Ivan
    Gisslinger, Heinz
    Drach, Johannes
    Kuhn, Ingrid
    Hinke, Axel
    Zojer, Niklas
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (09): : 1548 - 1554
  • [30] Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices
    Jagannath, Sundar
    Roy, Anuja
    Kish, Jonathan
    Lunacsek, Orsolya
    Globe, Denise
    Eaddy, Michael
    Kuriakose, Emil T.
    Willey, Joanne
    Butler-Bird, Stephanie
    Siegel, David
    EXPERT REVIEW OF HEMATOLOGY, 2016, 9 (07) : 707 - 717